Building the Future of Camino Science, Together
Your foundational AI platform has the potential to redefine biotech. This interactive proposal outlines a collaborative, data-driven partnership to transform Camino Science from a brilliant technology into a venture-backed, market-defining enterprise.
Challenge & Opportunity
Camino Science is at a critical inflection point. To attract premier investors in today's "flight to quality" market, we must address key milestones together.
Focus the Platform
Identify and validate the single most compelling market application to demonstrate clear product-market fit, a prerequisite for funding in a cautious market.
Complete the Team
Overcome the solo-founder hurdle. Data shows teams secure 83% of VC funding versus only 17% for individuals. This partnership immediately creates the balanced team investors want.
Prepare for Investment
Navigate the financial cleanup, address existing debt, and optimize the cap table to present a clean, professional, and de-risked opportunity to sophisticated institutional investors.
Our Joint Blueprint for Value Creation
A three-pillar action plan to systematically de-risk the company and unlock its full potential.
Pillar 1: Fundable Business Model
Lead a rigorous design thinking process to discover the most compelling application for the AI model, creating a data-driven business plan that transforms the core technology into an investable business.
Pillar 2: Secure Seed Funding
Spearhead a professional fundraising effort to secure a €5M-€10M seed round at a premium valuation from top-tier VCs, creating a competitive process to ensure the best terms.
Pillar 3: Build Leadership Team
Once funded, lead the executive search to recruit a permanent, world-class biotech CEO to ensure long-term success and allow the founder to focus on technical innovation.
Interactive Value Creation Model
The goal is not to divide the current pie, but to grow a much larger one. This model demonstrates how strategic partnership creates exponential value for all stakeholders.
Long-Term Value Projections
Select a scenario to see how the value of each stake grows through successive funding rounds.
| Stage | Investment (€M) | Valuation (€M) | Founder Value (€M) | Angel Value (€M) | Business 1 Value (€M) | Business 2 Value (€M) | ESOP Value (€M) | Investors Value (€M) |
|---|
Stakeholder Value Growth Over Time
A Fair and Aligned Partnership Structure
The proposed terms are designed to be transparent, founder-friendly, and grounded in market data to ensure a win-win structure.
We propose an equity stake of
11% each, dilutable
(22% combined), for creating over €17M in new enterprise value.
Market-Calibrated Justification
The Pre-Seed Biotech Standard
25%
A Cornell/VC analysis shows a founding scientist often receives 25% for providing the core technology. At this stage, architecting the business is the equivalent value-creating activity.
The Venture Builder Model
~34%
Venture studios that build companies from scratch with founders typically receive about one-third of the equity. Our proposed 22% combined stake is founder-friendly for this level of intensive involvement.
Co-Founder "Real World" Data
55%
Data from Carta shows that adding a second and third co-founder would typically cost 55% of the company's equity. Our proposal offers two C-level partners for the equity cost of roughly one typical co-founder.
Imperial's Founder's Choice
20%
For a 20% stake, this program offers institutional support to build a pharma spin-out. Our active, C-suite development roles are more hands-on.
Equity Distribution Comparison
This partnership creates a complete founding team (technical & business) for a successful fundraise. According to Carta, the median equity for a third co-founder is 22%. Our equity-efficient approach allows seed funds to hire a permanent C-suite later, when talent is far less dilutive.
Summary of Proposed Terms
No-Risk Trial
A 30-day no-obligation trial period allows either party to walk away, no strings attached, ensuring our collaboration is the right fit before any formal commitment.
100% Performance-Based Vesting
Our equity is 100% milestone-based, guaranteeing it is only earned on tangible results (investable model, seed funding, CEO hire). We take no salaries; our compensation is tied directly to the value we create.
Compensation
No salaries. A €75,000 success fee each, paid from seed proceeds we raise upon a successful close. This preserves pre-seed cash while rewarding delivery.
Founder Control
You retain control over key decisions. Major strategic changes require 75% shareholder consent, giving you effective veto power. You will maintain your board seat throughout.
Equity Stake
11% each (22% combined), dilutable. Bonus: 0.5% additional equity each if the seed valuation exceeds €12M.